The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non-transformed nodal, extranodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1-8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy-based high-dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub-group and more transplants performed in recent years in the other sub-groups. After a median follow-up of 5 years, 5-year cumulative incidence of relapse/progression and non-relapse mortality were 38% and 9%, respectively. Fiveyear event-free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five-year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.
Marginal zone lymphomas (MZL) represent a group of indolent B cell lymphomas deriving from the marginal zone of the secondary lymphoid follicles. MZL include three entities with a defined clinical and histological pattern: extra-nodal MZL of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) (Isaacson et al, 2008) , splenic MZL (SMZL) and nodal MZL (NMZL) . MZL generally have an indolent course and a favourable outcome (Bertoni et al, 2011; Thieblemont et al, 2012; Traverse-Glehen et al, 2012) , with a median survival longer than 12 years in MALT lymphoma and approximately 8 years in NMZL and SMZL, but a subset of patients may present a more aggressive course of the disease. Histological transformation and second malignancies have been reported to be leading risk factors for an unfavourable outcome in patients with MZL (Meyer et al, 2014) .
The low incidence of these lymphomas, their mostly indolent course, and the advanced age at diagnosis in most patients has precluded systematic investigation on the role of autologous stem cell transplantation (ASCT) in MZL. However, some data on ASCT in patients with MZL, largely from the pre-rituximab era, suggests the possibility of achieving long-term disease-free survival, but it is mostly anecdotal and based on very small series (Neumeister et al, 2000; Brown et al, 2004; Li et al, 2011) .
The present collaborative study aimed to investigate the characteristics and outcome of patients undergoing ASCT for MZL (MALT lymphoma, NMZL and SMZL) in the rituximab era, focusing on the anti-lymphoma activity provided by this procedure and its associated short-and long-term complications.
Patients and methods
Patients with MALT lymphoma, SMZL or NMZL aged ≥18 years, who underwent a first ASCT between July 1994 and February 2013, and were reported to the European Society for Blood and Marrow Transplantation (EBMT) registry, Fondazione Italiana Linfomi (FIL) or Gruppo Italiano Trapianto di Midollo Osseo (GITMO) networks were eligible for this study. Patients with a diagnosis of transformed MZL were excluded. The availability of a written diagnostic report for review was mandatory for inclusion. Patients were treated according to local protocols. Informed consent was obtained locally according to regulations applicable at the time of transplantation. As of January 2003, written informed consent was required before data registration in the EBMT registry. Specific informed consent was obtained from patients included from the FIL/GITMO groups.
Definitions
Disease response was defined according to the revised response criteria for lymphomas (Cheson et al, 1999) . Chemosensitivity was defined as the achievement of a complete remission (CR) or a partial remission (PR) with the chemotherapy regimen administered immediately preceding ASCT, whereas chemorefractory disease included primary refractory disease or refractory relapse before transplantation. CR1/PR1 indicates patients who underwent transplantation in first response, irrespective of the number of prior lines of therapy necessary to achieve this response. Transplantation in >CR1/PR1 included patients that were transplanted in second or later response. Response to ASCT was assessed at 100 days after transplantation.
Statistical analysis
Categorical variables were described by absolute and relative frequencies. Quantitative variables were summarised by median and interquartile range (IQR). The v 2 test or the Fisher's exact tests were used for testing associations among qualitative variables, as appropriate. Wilcoxon rank-sum and Kruskal Wallis tests were used to compare quantitative variables between two or more groups, respectively. The primary endpoints of the study were overall survival (OS) and event-free survival (EFS) defined according to the revised response criteria for lymphomas (Cheson et al, 1999) . The analysis also investigated cumulative incidence of relapse/progression (IR) (Andersen et al, 2002) , non-relapse mortality (NRM, defined as death from any cause in the absence of previous disease relapse or progression), and the cumulative incidence and type of second primary malignancies (SPM). The effect of prognostic factors on OS and EFS was evaluated using Cox regression models. IR, NRM and the cumulative incidence of SPM were estimated with a competing-risk approach, considering death from any cause as a competing event. Effect of risk factors for IR and NRM were estimated by the Fine and Gray model (Cox, 1972; Peto & Peto, 1972; Pepe & Mori, 1993; Fine & Gray, 1999; Andersen et al, 2002) . All variables with a prognostic impact in univariate analysis and those with special clinical interest were included in multivariate models.
All P values were considered statistically significant if P ≤ 0Á05 (two-tailed). The statistical analysis was conducted using the Stata Statistical Software: Release 12 (StataCorp. 2011: StataCorp LP, College Station, TX, USA).
Results

Patient characteristics at transplantation
From the initial cohort of 251 patients with MZL identified in the databases, 52 patients were excluded because of non- ASCT, autologous stem cell transplantation; BM, bone marrow; CR1, first complete remission; IQR, interquartile range; MALT, mucosa-associated lymphoid tissue; NMZL, nodal marginal zone lymphoma; PB, peripheral blood; PR1, first partial remission; SD, stable disease; SMZL, splenic marginal zone lymphoma; TBI, total body irradiation. *Conditioning regimens were: BEAM (carmustine, etoposide, cyctarbine, melphalan; n = 139); BEAC (carmustine, etoposide, cytarabine and cyclophosphamide;n = 9); BEAM-rituximab (n = 8); Z-BEAM (Zevalin + BEAM; n = 1); buslfan-melphalan (n = 2); CBV (cyclophosphamide, carmustine and etoposide;n = 5); FEAM (Fotemustine, etoposide, cytarabine, melphalan; n = 8); HD-CHOP (high dose cyclophosphamide, doxorubicin, vincristine, prednisone; n = 2); MEL140 ( confirmatory central review of the diagnostic report, documented histological transformation or missing data. Thus, the study sample consisted of 199 patients (154 from the EBMT registry and 45 from the FIL/GITMO series). The characteristics of the patients included in the study are detailed in Table I . One hundred and eleven patients were diagnosed with MALT lymphoma, 33 with SMZL and 55 with NMZL. No statistically significant differences were observed across the different MZL subtypes, with the exception of a lower percentage of patients previously treated with rituximab in the MALT lymphoma sub-group and more transplants performed in recent years in the other sub-groups.
The EBMT and FIL/GITMO series only differed with respect to the type of high-dose regimen reported (Table SI) .
Engraftment
Complete engraftment was reported in all but 2 patients [who died early (day +4 and +29) after ASCT]; engraftment was lost after an initial haematological recovery in one additional patient. The median time to neutrophil recovery in 194 patients in whom the data was available was 11 days (IQR, 10-13 days).
Disease response to transplant
Response information after ASCT was available in 176 patients. The best response achieved after ASCT was CR in 139 patients (79%) and PR in 30 patients (17%). Forty-nine patients (29%) improved their response to CR: 46 who were in PR prior to the transplant and 3 with SD before ASCT.
Outcome
After a median follow-up for alive patients of 5 years (IQR, 2Á4-7Á5), 58 patients (29%) had died. Thirty-three patients died due to disease progression (including 1 patient who died of secondary malignancy in the presence of active MZL) and 22 died in remission. Disease status at the time of death was unknown in 3 cases. Seventy-one patients (37%) relapsed or progressed at a median time of 16 months after ASCT (IQR, 6Á8-32Á5). Only 5 patients relapsed beyond 5 years of follow-up.
Five-and 10-year IR was 38% (95% confidence interval [CI], 30-45%) and 44% (95% CI, 35-53%), respectively (Fig 1) . Of note, the risk of relapse was 7Á5% per year for the first 5 years, 1Á3% per year for the next 5 years, and 0Á2% per year for the last 9 years.
Five and 10-year EFS was 53% (95% CI, 45-61%) and 42% (95% CI, 32-52%), respectively (Fig 2A) and OS at 5 and 10 years was 73% (95% CI, 65-79%) and 64% (95% CI, 54-78%), respectively (Fig 2B) , with no significant differences between the EBMT and the GITMO-FIL series (data not shown).
One-and five -year NRM was 6Á1%, (95% CI: 3Á2-10Á2%) and 9% (95% CI, 6-14%) respectively. Causes of death were bacterial infection (n = 5), haemorrhage (n = 3), cardiac toxicity (n = 2), viral infection (n = 2, with 1 case of CMV pneumonia), unspecified infection (n = 2), parasitic infection (n = 1), pulmonary toxicity (n = 2), second primary malignancies (SPM) (n = 4), car accident (n = 1) and unknown causes (n = 3). (Several patients had multiple complications resulting in death).
Second primary malignancies
Thirteen patients developed an SPM, resulting in a 5-year cumulative incidence of 6% (95% CI, 3-10%). The median time to the diagnosis of SPM was 39 months (range, 13Á5-91). SPM types were myelodysplastic syndrome (n = 3) mycosis fungoides (n = 1) and solid cancers (n = 9). In 5 of these patients (4 in continuing remission and 1 after relapse of the MZL) the secondary malignancy was reported as the main cause of death. There were no significant differences in the risk of SPM according to the histological subtype (data not shown). There was no impact of the number of prior lines of therapy or patient age at the time of transplant on the risk of SPM. Similarly, number of prior lines of therapy, 
Prognostic factors
Univariate analysis for OS is detailed in Table SII . Multivariate analysis (Table IIA) , considering age, histological subtype, chemosensitivity at transplantation, time from diagnosis, number of prior therapies, rituximab prior to ASCT, type of high-dose regimen and treatment period (assessed as a continuous variable), identified age ≥65 years to be the only significant predictor for a shorter OS (Fig 3A) . Additionally, the diagnosis of SMZL was associated with a trend for a shorter survival compared with the diagnosis of MALT lymphoma (Fig 3B) . Univariate analysis for EFS is shown in Table SII . On multivariate analysis (Table IIB) , age ≥65 years was the only significant factor affecting EFS.
Prognostic factors for IR on univariate analysis are shown in Table SII but multivariate analysis (Table IIC) failed to detect predictors for increased risk of relapse.
Both univariate (Table SII) and multivariate analysis (Table IID) failed to detect any factor that significantly affected NRM.
Outcome and prognostic factors for patients with MALT lymphoma
One hundred and eleven patients with MALT lymphoma underwent an ASCT. 5-year OS, EFS, IR and NRM in this subcohort was 77% (95% CI, 67-84%), 55% (95% CI, 44-65%), 38% (95% CI, 30-45%) and 9% (95% CI, 5-14%), respectively. On multivariate analysis, chemosensitive disease retained predictive value for OS (Table IIIA) and age retained predictive value for EFS (Table IIIB) and IR (Table IIIC) , with no prognostic factors identified for NRM (Table IIID) .
Discussion
The natural history and the clinical course of patients with MZL are generally indolent, with most patients responding to initial therapy (irradiation, immunotherapy or immunochemotherapy) and achieving durable remissions (Kahl & Yang, 2008; Thieblemont et al, 2016; Zucca et al, 2017) . A small proportion of patients experience disease progression less than 2-3 years from diagnosis and require subsequent salvage therapy (Thieblemont et al, 2016; Zucca & Bertoni, 2016; Zucca et al, 2017) . Treatment at progression is usually based on immuno-chemotherapy, preferably with agents that the patient has not previously been exposed to (Thieblemont et al, 2016) . The therapeutic role of agents targeting B-cell receptor signalling (Gopal et al, 2014; Noy et al, 2017) , new anti-CD20 monoclonal antibodies (Sehn et al, 2015) , and lenalidomide, although very promising, is still under investigation (Kiesewetter et al, 2013) . High-dose therapy, though potentially effective, is usually reserved for patients diagnosed with histological transformation (Villa et al, 2014; Yun et al, 2016) and rarely considered in patients with relapsed/progressed non-transformed MZL (Li et al, 2011) .
Our cohort represents, to our knowledge, the largest series of patients who underwent ASCT for non-transformed MZL. Half of these had required 2 or more lines of therapy to achieve this remission. Accordingly, a substantial number of patients had failed at least 2 prior lines of therapy, including rituximab (71%), before being considered for ASCT. Despite this, high-dose therapy followed by ASCT appears to be an effective approach for patients with relapsed/refractory MZL. The high conversion rate from PR or even SD to CR following transplantation and the extremely low rate of late relapses support this statement and suggests that ASCT can result in durable remissions. The 5-year EFS observed in our series compares favourably to that reported in several studies for novel agents and chemoimmunotherapy (Robinson et al, 2008; Rummel et al, 2016; Conconi et al, 2011 Conconi et al, , 2014 Kiesewetter et al, 2013; Noy et al, 2017) . Of note, our cohort also included a small group of patients transplanted as part of their initial therapy. These patients were younger and were transplanted in an earlier period than the remainder (data not shown). Unfortunately, due to the limitations inherent to a registry study, the reasons for ASCT as part of the initial therapy cannot be identified. Nevertheless, it is clear that transplantation in first line of treatment is not the current treatment practice.
Analysis of the whole series shows that the number of relapses decreases with time, with only 5 patients relapsing after 5 years of follow-up, suggesting a long duration of disease control with ASCT. Although this observation may also reflect a decline in patients at risk for relapse over time, the fact that the cumulative incidence of relapse decreases over time suggests this explanation to be less probable.
Our analysis also reveals an impressive long-term OS, much longer than the EFS, suggesting that the majority of patients that relapse after ASCT can be still salvaged, a statement which is likely to be even stronger nowadays, in the presence of a larger arena of anti-lymphoma therapies which can be introduced at disease progression (Kiesewetter et al, 2013; Gopal et al, 2014; Thieblemont et al, 2016; Noy et al, 2017) . Thus, the role of ASCT in the therapeutic algorithm of patients with MZL remains to be clearly defined.
Patients younger than 65 years old obtained the greatest benefit from ASCT in terms of OS and EFS. Patients with MALT lymphoma also had a superior outcome, especially when compared with patients with SMZL, attaining a 5-year OS of 77% vs. 61% (data not shown). This survival advantage was achieved in spite of a comparable risk of relapse and NRM, suggesting that patients with MALT lymphoma who relapse following ASCT have a higher chance to be salvaged compared with patients with SMZL, probably reflecting the natural differences in the biology and clinical course between these MZL subtypes (Arcaini et al, 2006; Zinzani, 2012) , although some studies, mainly performed in the rituximab era, proposed a non-inferior outcome of SMZL compared with MALT lymphoma (Else et al, 2012 Starr et al, 2017). Another explanation would be patient selection for transplantation, given the retrospective nature of our study. The relatively low proportion of rituximab-na€ ıve patients in our series precluded a reliable assessment of the impact of prior exposure to rituximab on transplant outcome. Nevertheless, according to our data, patients previously exposed to rituximab had similar outcomes compared with rituximabna€ ıve patients, suggesting that ASCT provides disease control even in rituximab-exposed patients. The short-term toxicity associated with transplantation was extremely low. However, the 5-year cumulative incidence of SPM was 6%. This risk seems to be lower than that reported in the study by Laudi et al (2005) , in long-term follicular lymphoma (FL) survivors that underwent an ASCT with a 4-year cumulative risk of SMP of 9%. The risk of SPM following ASCT has been mostly studied, for obvious reasons, in patients transplanted for FL. Older age (Darrington et al, 1994) and total body irradiation-based conditioning regimens (Darrington et al, 1994; Travis et al, 1996; Montoto et al, 2007) were suggested to be associated with an increased risk to develop SPM. Of note, risk factors reported in other series, such as age, number of previous lines or previous treatment with fludarabine were not found to be associated with a higher risk of SMP in our study. A recent retrospective survey that assessed risk factors for shortened survival in 197 MZL patients reported an annual SPM rate of 2Á7%, irrespective of the employment of high-dose therapy (Meyer et al, 2014) , that the high rate of SPM observed in our cohort might reflect a higher risk of MZL patients to develop SMP and not necessarily their prior exposure to high-dose therapy.
The present study suffers from all of the limitations associated with a retrospective study, including the analysis of a selected group of patients who underwent ASCT. Despite these obvious limitations, the current study, being the largest study published on ASCT in MZL, provides a comprehensive picture regarding the clinical features and outcome of MZL patients undergoing autograft. Novel therapies, though providing responses, may not result in durable long-term remissions. In conclusion, in the absence of clear guidelines on the role of ASCT in MZL, the low rate of late relapses following ASCT described here suggests that this approach may provide clinical benefit in patients with MZL, particularly in young patients that have failed multiple lines of chemoimmunotherapy.
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